J&J Wins Rapid Approval Of Specialized TB Drug

Law360, New York (January 2, 2013, 5:47 PM EST) -- The U.S. Food and Drug Administration on Monday announced it has granted early approval to Johnson & Johnson's Sirturo as the first medication for a rare and stubborn form of tuberculosis, saying the need for effective treatment outweighed lingering concerns about potentially deadly side effects.

Sirturo, or bedaquiline, is being developed by J&J unit Janssen Therapeutics and targets more than 600,000 patients around the world suffering from multidrug-resistant tuberculosis, a tough-to-fight strain of the bacterial lung infection that overall infects about 12 million people globally. Prevalence is...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.